Fund(s): FemTech Fund
Darshana Zaveri is a General Partner and a member of Catalyst’s investment committee. Darshana is actively involved in all aspects of Fund Management including Investments and Capital Raising. She led Catalyst’s investments in Augmenix, Lantos Technologies, nVision Medical, Maxwell Health, Aria CV and Hepregen and currently represents Catalyst on the Boards of Lantos (past Chair), nVision (acquired by Boston Scientific, NYSE: BSX, Aria CV, Augmenix and Maxwell Health and was actively involved with portfolio company Allegro Diagnostics (acquired by Veracyte, NASD: VER). Darshana has been the Acting CEO and President of Lantos Technologies since November 2016.
Darshana brings to Catalyst over a decade of experience in the health care and Life Science Industries. Prior to Catalyst, she was an Investigator at Vertex Pharmaceuticals and an integral part of the drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company, at the Dana Farber Cancer Institute and completed an internship at the United Nations. She has authored several publications and scientific journal articles and currently serves as a Catalyst of the Deshpande Center for Technological Innovation at MIT.
Darshana received an MPA from Harvard University, a Master in Cell and Molecular Biology from Boston University, and a BS in Biochemistry from Bombay University in Bombay, India.